Xyall

Private

EindhovenHealthcare & Life Scienceshttps://xyall.com/

Last Round

Series C

Feb 11, 2026

Total Funding Raised

$20.87M

Company Overview

Xyall is a medtech company that develops and provides automated tissue dissection solutions for molecular pathology testing.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotech Equipment, Precision Medicine, Workflow Automation, Industrial Robotics

Business Model

B2B

Customer Profile

Hardware Sales, Hardware + Subscription, Services & Consulting

AI Layer

Application

Keywords

automated tissue dissectionmolecular pathologylab automationrobotic tissue dissectiondigital pathologyprecision oncologynext-generation sequencingNGSpathology workflow automationcancer diagnosticsmedical devicesbiotech equipmenthigh-throughput screeningLIMS integrationcomputational pathology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Xyall Comps

Public and private peers based on sector, stage, and business model.

Xyall comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Xyall Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series C	Feb 11, 2026
Series B	May 24, 2022
Series A	Jan 13, 2020

View all Funding Rounds

Key People

Founding team and executive leadership

Mike Roele

COO

Executive Team

Xyall Investors

Notable investors and investment history

Xyall investors
Investor	Rounds
Brabantse Ontwikkelings Maatschappij	Series B
Capricorn Partners	Series C
BOM Brabant Ventures	Series C, Series A
Health Investment Partners	Series C, Series B
Netherlands Enterprise Agency	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Feb 23, 2026
Grew 58% QoQ, from 12 to 19 employees.
Feb 24, 2025
Grew 21% QoQ from 14 to 17 employees.

View all signals

Xyall Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Xyall Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Xyall's valuation, stock price, and market status.

Firmographic Details

HeadquartersEindhoven

Employee Range23

Year Founded2018

Last FundingFeb 11, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.